Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug ConjugateKevin J. Hamblett, Joseph A. Francisco, Peter D. Senter et al.|Clinical Cancer Research|2004Cited by 1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapySvetlana O. Doronina, Peter D. Senter, Michael Torgov et al.|Nature Biotechnology|2003Cited by 1.2k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityJoseph A. Francisco, Alan F. Wahl, Charles G. Cerveny et al.|Blood|2003Cited by 918
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicitySvetlana O. Doronina, Peter D. Senter, Brian A. Mendelsohn et al.|Bioconjugate Chemistry|2005Cited by 511
Contribution of Linker Stability to the Activities of Anticancer ImmunoconjugatesStephen C. Alley, Peter D. Senter, Dennis R. Benjamin et al.|Bioconjugate Chemistry|2008Cited by 464